{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-25-000060","form_type":"8-K/A","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.131756+00:00","generated_at":"2026-05-16T23:47:14.344592+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement","bullets":["First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.","Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.","Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.","Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-25-000060","json":"https://secwatch.observer/filing/0001680367-25-000060.json","markdown":"https://secwatch.observer/filing/0001680367-25-000060.md","text":"https://secwatch.observer/filing/0001680367-25-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/0001680367-25-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000060/sttk-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:47:14.344592+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}